HUTCHMED Starts Phase I Trial of Menin Inhibitor HMPL-506 in Hematological Malignancies
Details : HMPL-506 is a novel, investigational, selective small molecule inhibitor for oral administration targeting the menin protein. It is being investigated for MLL-rearranged relapsed/refractory AML.
Product Name : HMPL-506
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2024
Details : HMPL 415 is a novel, highly potent and selective allosteric inhibitor targeting SHP2, which is being developed in phase 1 trial for the treatment of Advanced Malignant Solid Tumors in China.
Product Name : HMPL-415
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 07, 2023
Lead Product(s) : Atezolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ARB202 (atezolizumab) is a first-in-class bispecific antibody based on Arbele's patented CDH17 biomarker. It targets both CDH17 on GI cancer as well as CD3 on T cells.
Product Name : ARB202
Product Type : Antibody
Upfront Cash : Inapplicable
February 08, 2023
Lead Product(s) : Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atezolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ARB202 is a first-in-class bispecific antibody based on Abele's patented CDH17 biomarker. The unique differential binding affinities of ARB202 toward CDH17 and CD3 allows it to have high specificity and cytotoxicity, while avoiding the "off-target" overa...
Product Name : ARB202
Product Type : Antibody
Upfront Cash : Inapplicable
October 08, 2022
Lead Product(s) : Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HMPL-A83 is an investigational IgG4-type humanized anti-CD47 monoclonal antibody that exhibits high affinity for CD47, blocks CD47 binding to Signal Regulatory Protein (SIRP) α and disrupts “do not eat me” signal that cancer cells use to shield them...
Product Name : HMPL-A83
Product Type : Antibody
Upfront Cash : Inapplicable
July 15, 2022
Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Baring Private Equity Asia
Deal Size : $100.0 million
Deal Type : Agreement
Hutchmed Announces US$100 Million Equity Investment by Baring Private Equity Asia
Details : The agreement will aid in company's business growth as it looks to ramp up its oncology revenues from ELUNATE®, SULANDA® and the potential upcoming approval of savolitinib, likely to be a first-in-class selective c-MET inhibitor in China.
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 04, 2021
Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Baring Private Equity Asia
Deal Size : $100.0 million
Deal Type : Agreement
Chi-Med starts Phase I Hematological Malignancies Study
Details : HMPL-306 is a selective, small molecule, dual inhibitor of isocitrate dehydrogenase (IDH) 1 and 2 mutations. It is the ninth oncology asset discovered by the company internally.
Product Name : HMPL-306
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Amdizalisib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chi-Med Highlights HMPL-689 Clinical Data to be Presented at the 62nd ASH Annual Meeting
Details : Abstract titled 'Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphoma" will be presented at the conference.
Product Name : HMPL-689
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 11, 2020
Lead Product(s) : Amdizalisib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable